| abstract |
The disclosure provides methods for treating vulvovaginal atrophy (VVA) and osteoporosis in breast cancer survivors and survivors of other malignancies with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. |